Infusible platelet membrane as a platelet substitute for transfusion: An overview

Blood Transfusion

Volumn 11, Issue 3, 2013, Pages 337-342

  Nasiri, Saleh ^a  

^a HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; HEMOSTATIC AGENT; THROMBOCYTE CONCENTRATE;

BLEEDING; HUMAN; REVIEW; THROMBOCYTE MEMBRANE; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; THROMBOGENICITY; ANIMAL; BLOOD CLOTTING; BLOOD COMPONENT THERAPY; MEMBRANE MICROPARTICLE; THROMBOCYTE;

ANIMALS; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; BLOOD PLATELETS; CELL-DERIVED MICROPARTICLES; HUMANS;

EID: 84882357422     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0209-12     Document Type: Review

References (90)

1. Boon GD. An overview of hemostasis. Toxicol Pathol 1993; 21: 170-9.
2. McNicol A, Israels SJ. Beyond hemostasis: The role of platelets in inflammation, malignancy and infection. Cardiovasc Hematol Disord Drug Targets 2008; 8: 99-117.
3. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 1991; 5: 146-54.
4. Bevers EM, Comfurius P, Zwaal RF. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983; 736: 57-66.
5. Lee VS, Taressenko L, Bellhouse BJ. Platelet transfusion therapy: platelet concentrate preparation and storage. J Lab Clin Med 1988; 111: 371-83.
6. Lee DH, Blajchman MA. Novel platelet products and substitutes. Transfus Med Rev 1998; 12: 175-87.
7. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
8. Heijnen HF, Schiel AE, Fijnheer R, et al. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-9.
9. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967; 13: 269-88.
10. Warren BA, Vales O. The release of vesicles from platelets following adhesion to vessel walls in vitro. Br J Exp Pathol 1972; 53: 206-15.
11. Nomura S. Function and clinical significance of plateletderived microparticles. Int J Hematol 2001; 74: 397-404.
12. Solberg C, Holme S, Little C. Morphological changes associated with pH changes during storage of platelet concentrates in first-generation 3-day container. Vox Sang 1986; 50: 71-7.
13. George JN, Pickett EB, Heinz R. Platelet membrane glycoprotein changes during the preparation and storage of platelet concentrates. Transfusion 1988; 28: 123-26.
14. Bode AP, Orton SM, Frye MJ, et al. Vesiculation of platelets during in vitro aging. Blood 1991; 77: 887-95.
15. George IN, Pickett EB, Heinz R. Platelet membrane microparticles in blood bank fresh frozen plasma and cryoprecipitate. Blood 1986; 68: 307-9.
16. Bode AP, Miller DT. Analysis of platelet factor 3 in platelet concentrates stored for transfusion. Vox Sang 1986; 51: 299-305.
17. Solberg C, Osterud B, Little C. Platelet storage lesion: formation of platelet fragments with platelet factor 3 activity. Thromb Res 1987; 48: 559-65.
18. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-34.
19. Lechner D, Weltermann A. Circulating tissue factor-exposing microparticles. Thromb Res 2008; 122 (Suppl 1): S47-54.
20. Key NS. Analysis of tissue factor positive microparticles. Thromb Res 2010; 125 (Suppl 1): S42-5.
21. Morel O, Toti F, Hugel B, et al. Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006; 26: 2594-604.
22. Owens MR, Holme S, Cardinali S. Platelet microvesicles adhere to subendothelium and promote adhesion of platelets. Thromb Res 1992; 66: 247-58.
23. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-97.
24. Burnier L, Fontana P, Kwak BR, et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-51.
25. Chao FC, Kim BK, Houranieh AM, et al. Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Transfusion 1996; 36: 536-42.
26. Graham SS, Gonchoroff NJ, Miller JL. Infusible platelet membranes retain partial functionality of the platelet GPIb/IX/V receptor complex. Am J Clin Pathol 2001; 115: 144-7.
27. Sahler J, Grimshaw K, Spinelli SL, et al. Platelet storage and transfusions: new concerns associated with old therapy. Drug Discov Today Dis Mech 2011; 8: e9-14.
28. Blumberg N, Heal JM, Rowe JM. A randomized trial of washed red blood cell and platelet transfusions in adult acute leukemia [ISRCTN76536440]. BMC Blood Disord 2004; 4: 6.
29. Vo TD, Cowles J, Heal JM, et al. Platelet washing to prevent recurrent febrile reactions to leucocyte-reduced transfusions. Transfus Med 2001; 11: 45-7.
30. Blumberg N, Heal JM, Gettings KF, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusionassociated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion 2010; 50: 2738-44.
31. Grimshaw K, Sahler J, Spinelli SL, et al. New frontiers in transfusion biology: Identification and significance of mediators of morbidity and mortality in stored red cell concentrates. Transfusion 2011; 51: 874-80.
32. Solberg C, Moen P, Little C. Effect of centrifugation on the storage properties of platelets. Vox Sang 1988; 55: 97-103.
33. Aursnes I, Vikholm V. On a possible interaction between ADP and mechanical stimulation in platelet activation. Thromb Haemost 1984; 51: 54-6.
34. Schoenfeld H, Muhm M, Doepfmer UR, et al. The Functional Integrity of platelets in volume-reduced platelet concentrates. Anesth Analg 2005; 100: 78-81.
35. Chu RW. Leukocytes in blood transfusion: adverse effects and their prevention. Hong Kong Med J 1999; 5: 280-84.
36. Chaudhary R, Aggarwal A, Khetan D, et al. Cytokine generation in stored platelet concentrate: comparison of two methods of preparation. Indian J Med Res 2006; 124: 427-30.
37. Dijkstra-Tiekstra MJ, van der Schoot CE, Pietersz RN, et al. White blood cell fragments in platelet concentrates prepared by the platelet-rich plasma or buffy-coat methods. Vox Sang 2005; 88: 275-7.
38. Hillyer CD, Josephson CD, Blajchman MA, et al. Bacterial contamination of blood components: risks, strategies, and regulation: joint ASH and AABB educational session in transfusion medicine. Hematology Am Soc Hematol Educ Program 2003: 575-89.
39. Bryant BJ, Klein HG. Pathogen inactivation: The definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131: 719-33.
40. Solheim BG. Pathogen reduction of blood components. Transfus Apher Sci 2008; 39: 75-82.
41. Erstad BL. Viral infectivity of albumin and plasma protein fraction. Pharmacotherapy 1996; 16: 996-1001.
42. Farcet MR, Kindermann J, Modrof J, et al. Inactivation of hepatitis A variants during heat treatment (pasteurization) of human serum albumin. Transfusion 2012; 52: 181-7.
43. Nasiri S, Sharifi Z. Evaluation of viral inactivation in suspension containing 20% albumin by pasteurization method. Iranian J Virol 2010; 4: 34-6.
44. Arakawa T, Kita Y. Stabilizing effects of caprylate and acetyltryptophanate on heat-induced aggregation of bovine serum albumin. Biochim Biophys Acta 2000; 1479: 32-6.
45. Nasiri S, Heidari M. Application of sodium caprylate as a stabilizer during pasteurization of infusible platelet membrane and evaluation of effectiveness by turbidity assay. Int J Analytical, Pharmaceutical Biomed Sci 2012; 1: 34-6.
46. Lee DH, Blajchman MA. Novel treatment modalities: new platelet preparations and substitutes. Br J Haematol 2001; 114: 496-505.
47. Roth GJ. Platelet arachidonate metabolism and plateletactivating factor. In: Phillips DR, Shuman MA, editors. Biochemistry of platelets. Orlando: Academic Press; 1986. p. 69-113.
48. Biro E, Akkerman JW, Hoek FJ, et al. The phospholipid composition and cholesterol content of platelet-derived microparticles: a comparison with platelet membrane fractions. J Thromb Haemost 2005; 3: 2754-63.
49. Morrell CN. Immunomodulatory mediators in platelet transfusion reactions. Hematology Am Soc Hematol Educ Program 2011; 2011: 470-4.
50. Alemany M, Hernandez MR, Bozzo J, et al. In vitro evaluation of the hemostatic effectiveness of non viable platelet preparations: studies with frozen-thawed, sonicated or lyophilized platelets. Vox Sang 1997; 73: 36-42.
51. Rinder HM, Snyder EL, Bonan JL, et al. Activation in stored platelet concentrates: correlation between membrane expression of P-selectin, glycoprotein IIb/IIIa, and betathromboglobulin release. Transfusion 1993; 33: 25-9.
52. Bevers EM, Comfurius P, van Rijn JL, et al. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
53. Sims PJ, Faioni EM, Wiedmer T, et al. Complement proteins C5b-9 cause release of membrane vesicles from the plateletsurface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-12.
54. Brox JH, Osterud B. Evidence for appearance of "lysis independent" procoagulant activities in collagen or thrombin stimulated platelets. Thromb Res 1983; 30: 449-58.
55. Bode AP, Eick L. Lysed platelets shorten the activated coagulation time (ACT) of heparinized blood. Am J Clin Pathol 1989; 91: 430-34.
56. Ahmadzadeh N, Yari F, Amirizadeh N, Khorramizadeh MR. Production and characterization of liquid-stored and lyophilized reconstituted human infusible platelet membranes. Int J Lab Hematol 2011; 33: 586-92.
57. Woods MC, Gamble FN, Furth J, et al. Control of the postirradiation hemorrhagic state by platelet transfusions. Blood 1953; 8: 545-53.
58. Jackson DP, Sorensen DK, Cronkite EP, et al. Effectiveness of transfusions of fresh and lyophilized platelets in controlling bleeding due to thrombocytopenia. J Clin Invest 1959; 38: 1689-97.
59. Firkin BG, Arimura G, Harrington WJ. A method for evaluating the hemostatic effect of various agents in thrombocytopenic rats and mice. Blood 1960; 15: 388-94.
60. Blajchman MA, Lee DH. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 1997; 11: 95-105.
61. Krishnamurti C, Maglasang P, Rothwell SW. Reduction of blood loss by infusion of human platelets in a rabbit kidney injury model. Transfusion 1999; 39: 967-74.
62. Hawksworth JS, Elster EA, Fryer D, et al. Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine. J Thromb Haemost 2009; 7: 1663-71.
63. Vostal JG, Reid TJ, Mondoro TH. Summary of a workshop on in vivo efficacy of transfused platelet components and platelet substitutes. Transfusion 2000; 40: 742-50.
64. Hjort PF, Perman V, Cronkite EP. Fresh, disintegrated platelets in radiation thrombocytopenia: Correction of prothrombin consumption without correction of bleeding. Proc Soc Exp Biol Med 1959; 102: 31-5.
65. McGill M, Fugman DA, Vittorio N, et al. Platelet membrane vesicles reduced microvascular bleeding times in thrombocytopenic rabbits. J Lab Clin Med 1987; 109: 127-33.
66. Nasiri S, Heidari M, Rivandi S. Evaluation of hemostatic effectiveness of infusible platelet membrane in rabbits as a potential substitute for platelet transfusion. J Drug Delivery Therapeutics 2012; 2: 1-3.
67. Nasiri S, Heidari M, Rivandi S. Infusible platelet membranes improve hemostasis: Studies with two different injection doses. Int J Pharmaceutical Sci Res 2012; 3: 4895-8.
68. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973; 5(2): 167-79.
69. McGill M, Brindley DC. Effects of storage on platelet reactivity to arterial subendothelium during blood flow. J Lab Clin Med 1979; 94: 370-80.
70. Escolar G, Hagert-Whiting K, et al. Interaction of long-term stored platelets with vascular subendothelium. J Lab Clin Med 1987; 109: 147-54.
71. Mazzara R, Escolar G, Garrido M, et al. Evaluation of the transfusion effectiveness of various platelet concentrates by means of an in vitro perfusion technique. Transfusion 1991; 31: 308-12.
72. Escolar G, Mazzara R, White JG, et al. Contribution of perfusion techniques to the evaluation of the hemostatic effectiveness of platelet concentrates. Blood Cells 1992; 18: 403-20.
73. Owens M, Holme S, Heaton A, et al. Post-transfusion recovery of function of 5-day stored platelet concentrates. Br J Haematol 1992; 80: 539-44.
74. Hernandez MR, Bozzo J, Mazzara R, et al. Platelet concentrates promote procoagulant activity: evidence from experimental studies using a perfusion technique. Transfusion 1995; 35: 660-5.
75. Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Studies of new in vitro thrombosis model with low molecular weight heparin as anticoagulant. Arteriosclerosis 1990; 10: 49-61.
76. Galan AM, Bozzo J, Hernández MR, et al. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions. Transfusion 2000; 40: 1074-80.
77. Galan AM, Hernandez MR, Bozzo J, et al. Preparations of synthetic phospholipids promote procoagulant activity on damaged vessels: studies under flow conditions. Transfusion 1998; 38: 1004-10.
78. Klein E, Farber S, Djerassi I, et al. The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. J Pediatrics 1956; 49: 517-22.
79. Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
80. Alving BM, Reid TJ, Fratantoni JC, et al. Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 1997; 37: 866-76.
81. Wooley DW, Edelman PM. Displacement of serotonin from tissues by a specific antimetabolite. Science 1958; 127: 281-2.
82. Klein E, Toch R, Farber S, et al. Hemostasis in thrombocytopenic bleeding following infusion of stored, frozen platelets. Blood 1956; 11: 693-9.
83. Jy W, Horstman LL, Arce M, et al. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-5.
84. Goodnough, LT, Kolodziej M, Ehlenbeck C. A phase I study of safety and efficacy for infusible platelet membrane in patients. Blood 1995; 86 (Suppl); 610a.
85. Scigliano E, Enright H, Telen M, et al. Infusible platelet membrane (IPM) for control of bleeding in thrombocytopenic patients. Blood 1997: 90 (Suppl); 267a.
86. Fitzpatrick GM, Cliff R, Tandon N. Thrombosomes: a plateletderived hemostatic agent for control of noncompressible hemorrhage. Transfusion 2013; 53 (Suppl 1): 100S-6S.
87. Bode AP, Orton SM, Frye MJ, Udis BJ. Vesiculation of platelets during in vitro aging. Blood 1991; 77: 887-95.
88. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16: 1-20.
89. Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-52.
90. Lehman CM, Blaylock RC, Alexander DP, Rodgers GM. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001; 47: 1204-11.